22 articles for HC Huang
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
3
Probes for narcotic receptor mediated phenomena. 9. Synthesis of (+/-)-(3 alpha,6a alpha,11a beta)-1,3,4,5,6,11a-hexahydro-2-methyl-2H-3,6a- methanobenzofuro[2,3-c]azocin-10-ol, an oxide-bridged 5-(m-hydroxyphenyl)morphan.
TBA
1
Discovery of an irreversible HCV NS5B polymerase inhibitor.
Merck Research Laboratories
11
Anti-inflammatory lanostanoids and lactone derivatives from Antrodia camphorata.
National Sun Yat-Sen University
1
Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase.
Merck Research Laboratories
69
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
Pfizer
47
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
Pfizer
67
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 2).
Pfizer
45
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1).
Pharmacia
41
Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationship.
Pfizer
13
Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
Pfizer
10
Selective cyclooxygenase inhibitors: Novel 4-spiro 1,2-diarylcyclopentenes are potent and orally active cox-2 inhibitors
TBA
8
Diaryl indenes and benzofurans: Novel classes of potent and selective cyclooxygenase-2 inhibitors
TBA
21
Discovery of nonpeptide potent conformationally restricted angiotensin II receptor antagonists
TBA
44
Optimized M24B Aminopeptidase Inhibitors for CARD8 Inflammasome Activation.
Memorial Sloan Kettering Cancer Center
20
Design, synthesis, and biological evaluation of pyrazinones containing novel P1 needles as inhibitors of TF/VIIa.
Pfizer
8
A novel class of apical sodium co-dependent bile acid transporter inhibitors: the 2,3-disubstituted-4-phenylquinolines.
Searle Discovery
35
Diarylspiro[2.4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationships.
Searle Research and Development
43
Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists.
Searle R&D
35
1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
Searle Research and Development